RA Capital Healthcare Fund LP 4
4 · Mineralys Therapeutics, Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Mineralys (MLYS) Director Derek DiRocco Receives 14,500 RSUs
What Happened
- Dr. Derek DiRocco, a Partner at RA Capital who serves on Mineralys Therapeutics’ board, was awarded a total of 14,500 restricted stock units (RSUs) on February 19, 2026. The filing shows two grants: 6,200 RSUs and 8,300 RSUs, each reported at $0.00 per share (no cash paid). These RSUs are contingent rights to receive one share of common stock upon vesting.
Key Details
- Transaction date: 2026-02-19; filing date: 2026-02-20 (appears timely).
- Grants: 6,200 RSUs (direct) and 8,300 RSUs (derivative-style RSUs) — total 14,500 RSUs; price reported $0.00 per share.
- Vesting: Footnote states RSUs vest in one annual installment following the grant date.
- Ownership/beneficial interest: RSUs are held for the benefit of RA Capital funds (RA Capital Healthcare Fund and RA Capital Nexus III Fund). RA Capital and related entities disclaim beneficial ownership except for pecuniary interest; Dr. DiRocco must turn over net cash or stock received on settlement to the Adviser to offset advisory fees.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Transaction code: A = Award/Grant.
Context
- RSU awards are compensation-type grants, not open-market purchases or sales, and do not by themselves indicate a buy/sell decision by the insider. Here, the awards are held for the benefit of institutional funds managed by RA Capital rather than being held personally by Dr. DiRocco. No immediate sale or exercise is reported.
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director
Transactions
- Award
Common Stock
[F1][F2][F3]2026-02-19+6,200→ 6,200 total(indirect: See footnotes) - Award
Stock Option (Right to Buy)
[F6][F2][F3]2026-02-19+8,300→ 8,300 total(indirect: See Footnote)Exercise: $28.06Exp: 2036-02-19→ Common Stock (8,300 underlying)
Holdings
- 5,456,521(indirect: See footnotes)
Common Stock
[F2][F4] - 1,867,229(indirect: See Footnote)
Common Stock
[F2][F5]
Footnotes (6)
- [F1]Restricted Stock Units (RSUs) are granted to Dr. Derek DiRocco for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F3]Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the RSUs and the options for the benefit of the Fund and the Nexus Fund III. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon settlement of the RSUs or exercise of the options, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
- [F4]Held directly by the Fund.
- [F5]Held directly by Nexus Fund III.
- [F6]The stock option vests in 12 substantially equal monthly installments following the date of grant.